舒肝解郁胶囊治疗肠易激综合征疗效观察

目的观察舒肝解郁胶囊治疗肠易激综合征（IBS）的效果。方法 60例IBS患者随机分为舒肝解郁组、黛力新（氟哌噻吨美利曲辛片）组和对照组。对照组给予马来酸曲美布汀和双歧杆菌活菌制剂口服;舒肝解郁组口服舒肝解郁胶囊0.72mg,2次/d;黛力新组口服氟哌噻吨美利曲辛片10.5mg,2次/d。疗程均为4周,观察3组患者的治疗总有效率,并比较焦虑自评量表（SAS）、抑郁自评量表（SDS）得分。结果治疗后舒肝解郁组和黛力新组患者SAS、SDS评分均较治疗前明显降低（P〈0.05）;总有效率、SAS、SDS二者差异无统计学意义（P〉0.05）,与对照组比较差异有统计学意义（P〈0.05）。3组均无明显不良反应。结论舒肝解郁胶囊治疗IBS在改善临床症状、降低不良情绪等方面与氟哌噻吨美利曲辛疗效相当,副作用少,值得临床推广。

Effect of shuganjieyu capsules for irritable bowel syndrome

Objective To observe the effect of shuganjieyu capsules for irritable bowel syndrome (IBS). Methods Sixty patients with IBS were randomly divided into three groups, shuganjieyue group, deanxit group and control group. Control group was treated with oral trimebutine maleate casules and bifidobiogen-livzon capsules. Shuganjieyu group was received 0.72 mg oral shuganjieyu capsules twice daily for 4 weeks. Deanxit group was received 10.5 mg oral Deanxit capsules twice daily for 4 weeks. Total effective rate of three groups were observed. Meanwhile, self-rating depression scale (SDS) and self-rating anxiety scale (SAS) were compared. Results In shuganjieyu group and deanxit group, SDS and SAS were significantly decreased (P < 0.05); the difference of total effective rates, SDS and SAS had no significant difference (P > 0.05). But the difference was obvious compared with control group (P < 0.05). All patients had no significant adverse effects. Conclusion Shuganjieyu capsule has exact curative effect for IBS.